Therapy Areas: Central Nervous System
Transine Therapeutics names new CEO
6 July 2021 -

Transine Therapeutics, a United Kingdom-based biotechnology company, announced on Monday that it has named Jan Thirkettle, PhD as its new chief executive officer.

Dr Thirkettle has around 25 years' experience of building cross-functional teams to drive delivery of innovative technologies. He was the start-up CEO of Freeline Therapeutics Holdings and more recently chief development officer. He has spent 18 years at GSK in various leadership roles from Discovery to Manufacturing. He has an MA in Chemistry and a PhD in Biological Chemistry from Oxford University.

Robbie Woodman, chairman of Transine's board of directors, said, 'Jan is a highly experienced leader with a proven track record of establishing novel platforms and developing new therapeutics, making him a perfect fit for Transine. His expertise in guiding biotechnology ventures across all stages of development and his deep scientific knowledge will be crucial in the development of Transine's pipeline of novel mRNA-targeted therapeutics, initially focused on central nervous system and ophthalmology indications. We are thrilled to have him join.'